Cell-Free DNA Collection Tube Industry Research：with a CAGR of approximately 7.1% during 2026–2032 The

Vivi

Right Now

Cell-Free DNA Collection Tube Industry Research：with a CAGR of approximately 7.1% during 2026–2032

The global market for Cell-Free DNA Collection Tube was estimated to be worth US$ 113 million in 2025 and is projected to reach US$ 181 million, growing at a CAGR of 7.1% from 2026 to 2032.

Global Market Research Publisher QYResearch (QY Research) announces the release of its latest report “Cell-Free DNA Collection Tube - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on 2025 market situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Cell-Free DNA Collection Tube market, including market size, market share, market volume, demand, industry development status, and forecasts for the next few years.

The report provides advanced statistics and information on global market conditions and studies the strategic patterns adopted by renowned players across the globe. As the market is constantly changing, the report explores competition, supply and demand trends, as well as the key factors that contribute to its changing demands across many markets.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5630907/cell-free-dna-collection-tube

Cell-Free DNA Collection Tubes are specialized evacuated blood collection tubes used for peripheral blood collection, anticoagulation, cellular stabilization, and preservation of cell-free DNA, typically consisting of medical-grade plastic tubes, vacuum-based draw structures, anticoagulants, cell stabilizers, sealing stoppers, and identification labels.
Their core function is to reduce leukocyte lysis, minimize genomic DNA contamination, maintain the original state of plasma cfDNA during collection, transportation, and temporary storage, and provide stable sample input for downstream nucleic acid extraction, library preparation, sequencing, PCR, or digital PCR analysis.
The global Cell-Free DNA Collection Tube market reached approximately US$113 million in 2025 and is expected to reach approximately US$181 million by 2032, with a CAGR of approximately 7.1% during 2026–2032, covering specialized evacuated tubes used for cfDNA collection, stabilization, transportation, and pre-analytical preservation.
Demand is mainly from non-invasive prenatal testing, oncology liquid biopsy, transplant monitoring, and other molecular diagnostic applications, driven by declining sequencing costs, expanding clinical use of liquid biopsy, centralization of testing laboratories, normalization of cross-regional sample transportation, and higher sample stability requirements from hospitals and third-party laboratories.
On the supply side, leading companies are investing in preservation reagent formulation, cell stabilization technology, regulatory certification, automated blood collection compatibility, cold-chain substitution, and global channel expansion, with the industry transitioning from a specialized high-end consumable segment to a standardized clinical testing consumable segment.
Future market growth will mainly come from increased oncology liquid biopsy testing volume, NIPT penetration in emerging markets, commercialization of transplant monitoring, and regional substitution opportunities for local brands.
The global cancer burden continues to rise, with about 20 million new cancer cases in 2022 and more than 35 million cases expected by 2050, providing a sustained demand background for ctDNA testing and related sample stabilization consumables, while growing recognition of ctDNA as a biomarker in clinical research and drug development further supports demand.
The market currently shows a competitive structure led by international molecular diagnostic consumable companies, specialized sample stabilization companies, and fast-growing regional life science consumable suppliers, with representative companies including Roche, Streck, QIAGEN, Norgen Biotek, SARSTEDT, Exact Sciences, Sekisui Medical, Zymo Research, MagBio Genomics, Nonacus, BD, Cwbio IT Group, Guangzhou Improve Medical Instruments, BEAVER, Lake Bio, Xiamen Zhixuan Biotechnology, and Magen Biotechnology.
The first tier mainly consists of international companies with molecular diagnostic platforms, global regulatory capabilities, hospital and third-party testing customer resources, and strong advantages in brand credibility, product validation data, quality systems, and global distribution.
The second tier includes specialized companies focused on sample stabilization, nucleic acid extraction, and life science consumables, usually differentiated by preservation duration, nucleic acid quality, research customer coverage, and flexible supply, while Chinese and other Asia-Pacific regional companies are mainly entering through local third-party medical testing laboratories, NIPT laboratories, oncology testing companies, and research customers.
Future competition will shift from price-oriented competition to integrated competition in stabilization performance, lot-to-lot consistency, regulatory compliance, platform compatibility, customer validation cycles, and supply chain responsiveness.
By capacity, Cell-Free DNA Collection Tubes are mainly classified into 5mL and 10mL types, with the 5mL format generally used for small-volume blood samples, selected research scenarios, pediatric or special blood collection situations, and targeted testing projects with lower sample volume requirements.
The 10mL format is more widely used in clinical and commercial molecular testing, as it provides more plasma volume and more stable cfDNA input for NIPT, oncology liquid biopsy, multi-gene testing, and cross-regional sample delivery workflows.
By application, non-invasive prenatal testing remains a mature and stable demand base supported by standardized testing workflows, large sample volume, and established channels, while oncology liquid biopsy is one of the fastest-growing applications driven by companion diagnostics, therapy guidance, recurrence monitoring, and MRD research, with higher requirements for sample stability, low-frequency mutation preservation, and transport tolerance.
Transplant monitoring is still in a penetration stage, and donor-derived cfDNA testing may create incremental demand, while other applications include genetic disease testing, research sequencing, drug development, and inflammation or organ injury-related research; overall, 10mL tubes and oncology liquid biopsy applications are expected to represent a faster-growing combination in the coming years.
Regionally, North America and Europe are the core markets with mature technical validation, clinical applications, and regulatory systems, with a high concentration of molecular diagnostic companies, liquid biopsy companies, central laboratories, and clinical research institutions, and strong acceptance of high-stability, high-consistency, and regulatory-compliant products.
The U.S. market remains a high-value demand center supported by oncology liquid biopsy, companion diagnostics, drug development, and commercial insurance coverage, while the European market has higher requirements for IVD regulation, clinical laboratory quality systems, and cross-border sample transfer, favoring suppliers with certification and channel capabilities.
China’s growth momentum mainly comes from its NIPT testing base, oncology precision medicine, expansion of third-party medical testing laboratories, improvement of the domestic molecular diagnostics supply chain, and increasing attention to standardized pre-analytical sample handling in hospitals.
Japan, South Korea, Singapore, and other Asia-Pacific markets are growing steadily, supported by advanced healthcare systems, cancer screening, and research testing demand, with future regional opportunities concentrated in local substitution in China and other emerging Asia-Pacific markets, higher liquid biopsy penetration, expansion of local third-party testing laboratories, and increasing demand for cross-border clinical research sample transportation.
The upstream supply chain includes medical-grade PET or PP tube materials, stoppers, blood collection needles and vacuum collection components, anticoagulants, cell stabilizers, nucleic acid protectants, labeling and barcode systems, sterile packaging materials, and automated assembly equipment.
The midstream segment includes formulation development, tube molding, reagent dosing, vacuum control, sealing, sterilization, batch quality control, and regulatory registration, while downstream customers include hospital laboratories, prenatal screening institutions, oncology testing companies, third-party medical laboratories, research institutions, pharmaceutical clinical trials, and transplant monitoring service providers.
Key barriers include preservation reagent stability, inhibition of cell lysis, performance maintenance under different temperatures and transportation conditions, lot-to-lot consistency, blood sample compatibility, automated testing platform compatibility, regulatory certification, and customer validation cycles, with higher-value links typically concentrated in stabilization reagent formulation, quality systems, clinical application validation, and brand channels.
The supply chain will become more regionalized, with localization of core reagents, deeper integration with nucleic acid extraction and sequencing workflows, and more customized supply and long-term framework procurement for large testing laboratories.
The policy and regulatory environment is pushing Cell-Free DNA Collection Tubes to evolve from research consumables into clinical diagnostic supporting consumables, as regulatory requirements for molecular diagnostics, liquid biopsy, and companion diagnostics become more stringent, leading customers to place higher requirements on quality systems, registration qualifications, biosafety, transportation stability, and testing result consistency.
Main industry challenges include different sample stability requirements across testing programs, long customer validation cycles, high entry barriers created by leading brands, increasing clinical evidence and registration costs, intensified price competition in some regions, and substitution pressure from standard EDTA tubes or other preservation options in low-end scenarios.
For new entrants, manufacturing capacity alone is insufficient to build long-term competitiveness; suppliers must also understand stabilization chemistry, molecular testing workflows, batch quality control, and customer application support.
In the coming years, the market will continue upgrading toward longer preservation windows, lower genomic DNA contamination, stronger temperature tolerance, higher automation compatibility, and more complete regulatory compliance, with NIPT maintaining a stable demand base, oncology liquid biopsy becoming the major growth engine, and transplant monitoring and pharmaceutical clinical trials forming new high-value applications.
As the importance of pre-analytical sample handling in molecular diagnostics becomes increasingly recognized, Cell-Free DNA Collection Tubes will gradually become a critical link affecting test sensitivity, result reliability, and laboratory operating efficiency, and companies with proven product performance, global regulatory strategies, testing platform collaboration, and regional supply chain responsiveness are expected to gain higher market share and stronger customer stickiness.

The report provides a detailed analysis of the market size, growth potential, and key trends for each segment. Through detailed analysis, industry players can identify profit opportunities, develop strategies for specific customer segments, and allocate resources effectively.

The Cell-Free DNA Collection Tube market is segmented as below:
By Company
Roche
Streck
QIAGEN
Norgen Biotek
SARSTEDT
Exact Sciences
Sekisui Medical
Zymo Research
MagBio Genomics
Nonacus
BD
Cwbio IT Group
Guangzhou Improve Medical Instruments
BEAVER
Lake Bio
Xiamen Zhixuan Biotechnology
Magen Biotechnology

Segment by Type
5mL
10mL
Others

Segment by Application
NIPT
Oncology Liquid Biopsy
Transplant Monitoring
Others

Each chapter of the report provides detailed information for readers to further understand the Cell-Free DNA Collection Tube market:

Chapter 1: Introduces the report scope of the Cell-Free DNA Collection Tube report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. (2021-2032)
Chapter 2: Detailed analysis of Cell-Free DNA Collection Tube manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. (2021-2026)
Chapter 3: Provides the analysis of various Cell-Free DNA Collection Tube market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. (2021-2032)
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.(2021-2032)
Chapter 5: Sales, revenue of Cell-Free DNA Collection Tube in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world..(2021-2032)
Chapter 6: Sales, revenue of Cell-Free DNA Collection Tube in country level. It provides sigmate data by Type, and by Application for each country/region.(2021-2032)
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. (2021-2026)
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Benefits of purchasing QYResearch report:

Competitive Analysis: QYResearch provides in-depth Cell-Free DNA Collection Tube competitive analysis, including information on key company profiles, new entrants, acquisitions, mergers, large market shear, opportunities, and challenges. These analyses provide clients with a comprehensive understanding of market conditions and competitive dynamics, enabling them to develop effective market strategies and maintain their competitive edge.

Industry Analysis: QYResearch provides Cell-Free DNA Collection Tube comprehensive industry data and trend analysis, including raw material analysis, market application analysis, product type analysis, market demand analysis, market supply analysis, downstream market analysis, and supply chain analysis.

and trend analysis. These analyses help clients understand the direction of industry development and make informed business decisions.

Market Size: QYResearch provides Cell-Free DNA Collection Tube market size analysis, including capacity, production, sales, production value, price, cost, and profit analysis. This data helps clients understand market size and development potential, and is an important reference for business development.

Other relevant reports of QYResearch:
Global Cell-Free DNA Collection Tube Market Outlook, In‑Depth Analysis & Forecast to 2032
Global Cell-Free DNA Collection Tube Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
Global Cell-Free DNA Collection Tube Market Research Report 2026

To contact us and get this report: https://www.qyresearch.com/contact-us

About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 19 years of experience and a dedicated research team, we are well placed to provide useful information and data for your business, and we have established offices in 7 countries (include United States, Germany, Switzerland, Japan, Korea, China and India) and business partners in over 30 countries. We have provided industrial information services to more than 60,000 companies in over the world.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp